BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36800548)

  • 1. Pembrolizumab with chemotherapy, with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer.
    McNamara B; Chang Y; Mutlu L; Harold J; Santin AD
    Expert Opin Biol Ther; 2023 Mar; 23(3):227-233. PubMed ID: 36800548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
    Nishio S; Yonemori K; Usami T; Minobe S; Yunokawa M; Iwata T; Okamoto A; Aoki Y; Itamochi H; Takekuma M; Harano K; Yamamoto K; Maruko T; Ugai H; Tekin C; Colombo N; Fujiwara K; Hasegawa K; Ushijima K
    Cancer Sci; 2022 Nov; 113(11):3877-3887. PubMed ID: 35792064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
    Barrington DA; Riedinger C; Haight PJ; Tubbs C; Cohn DE
    Gynecol Oncol; 2022 Jun; 165(3):500-505. PubMed ID: 35422338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe hematuria in a patient receiving bevacizumab and pembrolizumab for metastatic cervical cancer: a case report.
    Liu Y; Dong C; He X; Wu P; Shu Y; Chen L
    BMC Nephrol; 2023 Mar; 24(1):51. PubMed ID: 36899322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
    Monk BJ; Colombo N; Tewari KS; Dubot C; Caceres MV; Hasegawa K; Shapira-Frommer R; Salman P; Yañez E; Gümüş M; Olivera Hurtado de Mendoza M; Samouëlian V; Castonguay V; Arkhipov A; Tekin C; Li K; Keefe SM; Lorusso D;
    J Clin Oncol; 2023 Dec; 41(36):5505-5511. PubMed ID: 37910822
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
    Shi Y; Chen J; Shi B; Liu A
    Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab for advanced cervical cancer: safety and efficacy.
    De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
    Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
    Dafni U; Tsourti Z; Vervita K; Peters S
    Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non-Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer.
    Rosen VM; Guerra I; McCormack M; Nogueira-Rodrigues A; Sasse A; Munk VC; Shang A
    Int J Gynecol Cancer; 2017 Jul; 27(6):1237-1246. PubMed ID: 28448304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer.
    Mutlu L; Tymon-Rosario J; Harold J; Menderes G
    Expert Rev Anticancer Ther; 2022 Jun; 22(6):633-645. PubMed ID: 35533682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab for the treatment of cervical cancer.
    Marret G; Borcoman E; Le Tourneau C
    Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
    [No Abstract]   [Full Text] [Related]  

  • 16. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress on clinical application of bevacizumab for the treatment of refractory cervical cancer].
    He B; Chai Y; Wang T; Zhou Z; Liu Z
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):395-402. PubMed ID: 27868413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
    Vergote I; Van Nieuwenhuysen E; O'Cearbhaill RE; Westermann A; Lorusso D; Ghamande S; Collins DC; Banerjee S; Mathews CA; Gennigens C; Cibula D; Tewari KS; Madsen K; Köse F; Jackson AL; Boere IA; Scambia G; Randall LM; Sadozye A; Baurain JF; Gort E; Zikán M; Denys HG; Ottevanger N; Forget F; Mondrup Andreassen C; Eaton L; Chisamore MJ; Viana Nicacio L; Soumaoro I; Monk BJ
    J Clin Oncol; 2023 Dec; 41(36):5536-5549. PubMed ID: 37651655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for recurrent, persistent or advanced cervical cancer: reproducibility of GOG 240 study results in "real world" patients.
    Godoy-Ortiz A; Plata Y; Alcaide J; Galeote A; Pajares B; Saez E; Alba E; Sánchez-Muñoz A
    Clin Transl Oncol; 2018 Jul; 20(7):922-927. PubMed ID: 29222647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of bevacizumab with chemotherapy doublets for advanced cervical cancer.
    Krill LS; Tewari KS
    Expert Opin Pharmacother; 2015 Apr; 16(5):675-83. PubMed ID: 25643984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.